Key Highlights

  • Entegris is scheduled to report third-quarter 2026 results on 29 October 2026, before the US market opens.
  • Second-quarter net sales were US$883.2 million, up about 11.5%, with non-GAAP Diluted Earnings per Share of US$0.93.
  • Third-quarter net sales are guided to US$905 million to US$935 million, and long-term Debt was US$3,456.0 million at 27 June.

Results due on Thursday

Entegris, Inc. (NASDAQ:ENTG) is scheduled to report third-quarter 2026 results on 29 October 2026, before the US market opens, according to the company's 1 October announcement. The quarter ended on 26 September 2026. Second-quarter sales and earnings per share both rose year on year, so the third-quarter report is the first test of whether that momentum continued into the following quarter.

The second-quarter baseline

In its second-quarter report, released on 4 August 2026 for the quarter ended 27 June, Entegris reported net sales of US$883.2 million, up about 11.5% from US$792.4 million a year earlier and about 8.8% from the first quarter. Advanced Purity Solutions sales were US$514.6 million, up about 17.0%, while Materials Solutions sales were US$371.3 million, up about 4.6%.

GAAP diluted earnings per share were US$0.61, compared with US$0.35 a year earlier, and non-GAAP diluted earnings per share were US$0.93, compared with US$0.66. GAAP Net Income was US$93.6 million and non-GAAP net income US$142.7 million.

Margins and the balance sheet

Adjusted operating Margin rose to 24.5% from 20.9% a year earlier, and adjusted EBITDA margin to 28.4% from 27.3%. GAAP gross margin was 47.6%, against 44.4%. Segment profit for Advanced Purity Solutions was US$150.9 million, compared with US$95.9 million, and for Materials Solutions US$77.7 million, compared with US$72.5 million.

Operating cash flow was US$156.2 million in the quarter, up from US$113.5 million a year earlier, with Capital Expenditure of US$39.3 million. The company repaid US$200.0 million of debt in the quarter. Long-term debt was US$3,456.0 million at 27 June, down from US$3,697.6 million at the end of 2025, and cash and equivalents were US$353.6 million.

Debt remains a significant part of the story. Year to date, Operating Cash Flow was US$339.2 million and capital expenditure US$80.8 million, which leaves cash available to service that debt.

What management guided

For the third quarter, Entegris guided to net sales of US$905 million to US$935 million, GAAP diluted earnings per share of US$0.75 to US$0.83, and non-GAAP diluted earnings per share of US$0.96 to US$1.04. It expects adjusted EBITDA of about 28.0% to 29.0% of sales.

These are management forecasts. The report on 29 October will show whether results landed within those ranges.

A portfolio change

On 20 October 2026, it was announced that Savillex had acquired Entegris' life sciences fluid management business, which includes bioprocessing and pharmaceutical Manufacturing solutions. The announcement did not disclose the price or say whether the transaction has closed, so its financial effect cannot yet be judged.

What to watch

Items to watch include sales within the guided range, the direction of adjusted EBITDA margin relative to the 28.4% reported last quarter, continued debt reduction, and any detail on the life sciences disposal. The performance of the two segments, and of operating cash flow compared with the US$156.2 million last quarter, is also relevant, given the faster growth in Advanced Purity Solutions.